The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer
- 1 October 2003
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 42 (1) , 69-77
- https://doi.org/10.1016/s0169-5002(03)00245-9
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Long-Term Results of Combined-Modality Therapy in Resectable Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- A randomized trial of systematic nodal dissection in resectable non-small cell lung cancerLung Cancer, 2002
- Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung CancerNew England Journal of Medicine, 2000
- Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancerThe Annals of Thoracic Surgery, 2000
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Results of cancer and leukemia group B protocol 8935The Journal of Thoracic and Cardiovascular Surgery, 1995
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994
- Randomized trial of neoadjuvant therapy for lung cancer: Interim analysisThe Annals of Thoracic Surgery, 1992